All In Biotech

Drug Trial Radar · NCT06128148

Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of JYP0322 in Patients With Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jul 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

101

Planned (sponsor's estimate)

Start

May 4, 2022

Primary completion

Jun 30, 2026

Study completion Dec 30, 2027

Sponsor

Lead sponsor
Guangzhou JOYO Pharma Co., LtdIndustry
Sponsor type
Industry
First posted
Nov 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open, non-randomized, multicenter, single-arm dose-escalation design, phase 1 trial to study the safety, tolerability, pharmacokinetics and efficacy of JYP0322 in patients with ROS1+ locally advanced/metastatic solid tumors .

Conditions

  • Protein Kinase Inhibitors
  • Other Protocol Specified Criteria
  • Lung Neoplasms
  • Brain Neoplasms

Interventions

  • JYP0322 50 mg qdDrug

    JYP0322 is administered orally at a dose of 50 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.

  • JYP0322 100 mg qdDrug

    JYP0322 is administered orally at a dose of 100 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.

  • JYP0322 200 mg qdDrug

    JYP0322 is administered orally at a dose of 200 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.

  • JYP0322 100 mg bidDrug

    JYP0322 is administered orally at a dose of 100 mg bid for a specified duration until unacceptable toxicity, disease progression, or study completion.

  • JYP0322 150 mg bidDrug

    JYP0322 is administered orally at a dose of 150 mg bid for a specified duration until unacceptable toxicity, disease progression, or study completion.

  • JYP0322 200 mg bidDrug

    JYP0322 is administered orally at a dose of 200 mg bid for a specified duration until unacceptable toxicity, disease progression, or study completion.

  • JYP0322 150mg tidDrug

    JYP0322 is administered orally at a dose of 150 mg tid for a specified duration until unacceptable toxicity, disease progression, or study completion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The frequency and severity of adverse events of JYP0322Time frame: From the date of informed consent through 30 days after the last dose of study drug, approximately up to 36 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-Sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.